At a time when UK biotechs have struggled to access funds, Achilles Therapeutics Ltd. has bucked the trend, raising an impressive £100m to advance its personalized cancer immunotherapies targeting clonal neoantigens into the clinic.
New investor RA Capital led the series B round which included founding backer Syncona additional new investors Forbion Capital Partners,...